NUTM2A and glioma: Across diverse malignancies—including gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, and prostate cancer—NUTM2A-AS1 has emerged as a critical regulator of tumor progression.